CSIMarket



Biogen Inc   (BIIB)
Other Ticker:  
 
 

BIIB's Revenue Growth by Quarter and Year

Biogen Inc 's Revenue results by quarter and year




BIIB Revenue (in millions $) FY 2022 FY 2021 FY 2020 FY 2019
IV Quarter December - 2,733.80 2,852.60 3,671.30
III Quarter September - 2,778.90 3,376.10 3,600.10
II Quarter June - 2,775.00 3,681.60 3,616.70
I Quarter March 2,531.80 2,694.00 3,534.30 3,489.80
FY   2,531.80 10,981.70 13,444.60 14,377.90



BIIB Revenue first quarter 2022 Y/Y Growth Comment
Biogen Inc reported decrease in Revenue in the first quarter 2022 by -6.02% to $ 2,531.80 millions, from the same quarter in 2021.
The decrease in the first quarter 2022 Biogen Inc 's Revenue compares unfavorably to the Company's average Revenue growth of 2.41%.

Looking into first quarter 2022 results within Biotechnology & Pharmaceuticals industry 8 other companies have achieved higher Revenue growth. While Biogen Inc ' s Revenue decline of -6.02% ranks overall at the positon no. 766 in the first quarter 2022.




BIIB Revenue ( Y/Y Growth %) 2022
2021 2020 2019
IV Quarter December - -4.16 % -22.3 % 4.11 %
III Quarter September - -17.69 % -6.22 % 4.68 %
II Quarter June - -24.63 % 1.79 % 7.75 %
I Quarter March -6.02 % -23.78 % 1.28 % 11.46 %
FY   - -18.32 % -6.49 % 6.88 %

Financial Statements
Biogen Inc 's first quarter 2022 Revenue $ 2,531.80 millions BIIB's Income Statement
Biogen Inc 's first quarter 2021 Revenue $ 2,694.00 millions Quarterly BIIB's Income Statement
New: More BIIB's historic Revenue Growth >>


BIIB Revenue (Quarter on Quarter Growth %)

2022
2021 2020 2019
IV Quarter December - -1.62 % -15.51 % 1.98 %
III Quarter September - 0.14 % -8.3 % -0.46 %
II Quarter June - 3.01 % 4.17 % 3.64 %
I Quarter March -7.39 % -5.56 % -3.73 % -1.04 %
FY (Year on Year)   - -18.32 % -6.49 % 6.88 %




Revenue first quarter 2022 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #9
Healthcare Sector #76
Overall #766

Revenue Y/Y Growth Statistics
High Average Low
10.31 % 2.41 % -7.19 %
(March 31, 2014)   (Jun 30 2021)
Revenue first quarter 2022 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #9
Healthcare Sector #76
Overall #766
Revenue Y/Y Growth Statistics
High Average Low
10.31 % 2.41 % -7.19 %
(March 31, 2014)   (Jun 30 2021)

Revenue by Quarter for the Fiscal Years 2019, 2020, 2021, 2022

Biogen Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
80.67 % 3.39 % -15.51 %
(March 31, 2004)  


BIIB's I. Quarter Q/Q Revenue Comment
In the I. Quarter 2022 Biogen Inc realized drop in Revenue from the previous quarter by -7.39% to $ 2,531.80 millions, from $ 2,733.80 millions achived a quarter before.

When you analyse current shortcoming at the I. Quarter, you must presume, that usually I. Quarter 2022 results occur sluggish relative to the forth quarter

Within Biotechnology & Pharmaceuticals industry 6 other companies have achieved higher Revenue quarter on quarter growth. While Biogen Inc 's Revenue growth quarter on quarter, overall rank is 627.


Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #7
Healthcare Sector #62
Overall #627
Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #7
Healthcare Sector #62
Overall #627
Revenue Q/Q Growth Statistics
High Average Low
80.67 % 3.39 % -15.51 %
(March 31, 2004)  


BIIB's I. Quarter Q/Q Revenue Comment
In the I. Quarter 2022 Biogen Inc reported drop in Revenue from the previous quarter by -7.39% to $ 2,531.80 millions, from $ 2,733.80 millions achived in the previous reporting period.

This is not big concern, as Biogen Inc 's Revenue always seem to dip in the I. Quarter Chelsey Pereira, market contributor wrote.

Within Biotechnology & Pharmaceuticals industry 6 other companies have achieved higher Revenue quarter on quarter growth. While Biogen Inc 's Revenue growth quarter on quarter, overall rank is 627.


Biogen Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Mar 31 2022)
12 Months Ending
(Dec 31 2021)
12 Months Ending
(Sep 30 2021)
12 Months Ending
(Jun 30 2021)
12 Months Ending
(Mar 31 2021)
Cumulative Revenue 12 Months Ending $ 10,819.50 $ 10,981.70 $ 11,100.50 $ 11,697.70 $ 12,604.30
Y / Y Revenue Growth (TTM) -14.16 % -18.32 % -22.17 % -19.26 % -12.61 %
Year on Year Revenue Growth Overall Ranking # 818 # 401 # 123 # 151 # 2672
Seqeuential Revenue Change (TTM) -1.48 % -1.07 % -5.11 % -7.19 % -6.25 %
Seq. Revenue Growth (TTM) Overall Ranking # 766 # 2793 # 125 # 3566 # 3324




Cumulative Revenue growth Comment
Biogen Inc showed decline, but improvement compare to trailing twelve month Revenue decrease in Dec 31 2021. If the fiscal year would end in Mar 31 2022, Biogen Inc 's annual Revenue decline would be -14.16% year on year to $10,820 millions.

In the Healthcare sector 71 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 401 to 818.

Revenue TTM Q/Q Growth Statistics
High Average Low
10.31 %
2.41 %
-7.19 %
 

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 9
Healthcare Sector # 72
Overall # 818

Revenue TTM Y/Y Growth Statistics
High Average Low
41.42 %
10.95 %
-22.17 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 9
Sector # 76
S&P 500 # 766
Cumulative Revenue growth Comment
Biogen Inc showed decline, but improvement compare to trailing twelve month Revenue decrease in Dec 31 2021. If the fiscal year would end in Mar 31 2022, Biogen Inc 's annual Revenue fall would be -14.16% year on year to $10,820 millions.

In the Healthcare sector 71 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 401 to 818.

Revenue TTM Q/Q Growth Statistics
High Average Low
10.31 %
2.41 %
-7.19 %
 


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 9
Healthcare Sector # 72
Overall # 818

Revenue TTM Y/Y Growth Statistics
High Average Low
41.42 %
10.95 %
-22.17 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 9
Sector # 76
S&P 500 # 766




Other Revenue Growth
Biotechnology & Pharmaceuticals Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
BIIB's Revenue Growth Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth
Revenue Growth for BIIB's Competitors
Revenue Growth for Biogen Inc 's Suppliers
Revenue Growth for BIIB's Customers

You may also want to know
BIIB's Annual Growth Rates BIIB's Profitability Ratios BIIB's Asset Turnover Ratio BIIB's Dividend Growth
BIIB's Roe BIIB's Valuation Ratios BIIB's Financial Strength Ratios BIIB's Dividend Payout Ratio
BIIB's Roa BIIB's Inventory Turnover Ratio BIIB's Growth Rates BIIB's Dividend Comparisons



Companies with similar Revenue fall for the quarter ending Mar 31 2022 within Healthcare SectorY/Y Change %Revenue for the quarter ending Mar 31 2022
Hydrofarm Holdings Group Inc -0.01%$ -0.011 millions
Sage Therapeutics Inc -0.06%$ -0.063 millions
Davita Inc -0.09%$ -0.087 millions
Axogen inc -0.10%$ -0.097 millions
Oncternal Therapeutics Inc -0.27%$ -0.267 millions
World Health Energy Holdings Inc.-0.33%$ -0.328 millions
Glaukos Corp-0.42%$ -0.422 millions
Collegium Pharmaceutical inc -0.70%$ -0.699 millions
Tenet Healthcare Corp-0.75%$ -0.753 millions
Nevro Corp -0.87%$ -0.867 millions
Antares Pharma Inc -1.25%$ -1.250 millions
Elanco Animal Health Inc-1.37%$ -1.369 millions
Nanostring Technologies Inc -1.70%$ -1.698 millions
Mimedx Group Inc -1.79%$ -1.789 millions
Exagen Inc -1.82%$ -1.823 millions
Royalty Pharma Plc-1.92%$ -1.916 millions
Veru Inc -2.34%$ -2.339 millions
Delcath Systems Inc -2.58%$ -2.577 millions
Ikena Oncology Inc -2.59%$ -2.591 millions
Therapeuticsmd Inc -2.68%$ -2.683 millions
Ngm Biopharmaceuticals Inc -2.91%$ -2.906 millions
Livanova Plc-3.00%$ -3.000 millions
Lifevantage Corp-3.04%$ -3.037 millions
Reata Pharmaceuticals Inc -3.18%$ -3.178 millions
Bio rad Laboratories Inc -3.68%$ -3.678 millions
Codiak Biosciences Inc -3.69%$ -3.692 millions
Vanda Pharmaceuticals Inc -3.95%$ -3.953 millions
Quest Diagnostics Inc-4.01%$ -4.007 millions
Organogenesis Holdings Inc -4.32%$ -4.325 millions
Myriad Genetics Inc -4.74%$ -4.737 millions


       
Economy


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production

Productivity

Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales

Stocks


Event Calendar

BTBD's Profile

Stock Price

BTBD's Financials

Business Description

Fundamentals

Charts & Quotes

BTBD's News

Suppliers

BTBD's Competitors

Customers & Markets

Economic Indicators

BTBD's Growth

Company Segments

Screening


Stock Performance

Growth Rates

Profitability

Valuation

Dividend

Financial Strength

Efficiency

Largest Companies

Management Effectivness

Industries


At a Glance

Performance

Growth Rates

Profitability

Valuation

Financial Strength

Markets


At a Glance

Stocks

Cryptocurrencies

Sectors & Industries

Commodities

Currencies

Help


Sitemap

Advertise

About us

Glossary


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.    Copyright © 2022 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071